Nova Biomedical Announces the Integration of NanoCellect Products into Their Cell Line Advancement Workflows

On 24 July 2026, Nova Biomedical incorporated the NanoCellect Portfolio to improve cell line development, automate analysis, foster bioprocess innovation, and advance biopharmaceutical research, supporting faster, more efficient, and scalable therapeutic development.

Nova Biomedical integrated NanoCellect's products to enhance cell line development for biotech and biopharma, combining analytical and cell-sorting technologies for efficient biologics manufacturing and therapeutic discovery. NanoCellect's gentle microfluidic sorting isolates healthy cells, boosting productivity by achieving industry demand for precise, productive lab processes. 

This move advances interconnected lab ecosystems that combine analytics, automation, and cell technology, strengthening Nova's prospects in life sciences and speeding up next-generation biologics and therapies. It increases efficiency, consistency, and regulatory compliance, building a competitive edge by fostering broader use across research and commercial labs. The merge accelerates screening, reduces manual work, and shortens development timelines, supporting automation and data-driven bioprocessing.

Impact on the Biotechnology Industry 

The global biotechnology market size is accounted at USD 1.77 trillion in 2025 and predicted to increase from USD 2.02 trillion in 2026 to approximately USD 6.34 trillion by 2035, representing a CAGR of 13.61% from 2026 to 2035. 

According to Precedence Research, the partnership encourages platform adoption, and biologics dominate the pharma industry. Integrating NanoCellect products with Nova Biomedical can improve cell line development, a decisive step in the production of biologics such as monoclonal antibodies and gene therapies. Combining cell sorting with analysis enables the identification of optimal cells, preservation of viability, and support for lab automation and digital workflows.

Nova's offerings enhance biotech innovation and research efficiency. Automated systems reduce variability, ensuring consistency for complex therapies and regulatory approval. The success rate increase from small efficiency gains can shorten timelines, speeding up early research, cutting costs, and accelerating promising projects, especially in oncology and regenerative medicine.

Impact on the Biopharmaceutical Industry

The global biopharmaceuticals market size is calculated at USD 537.54 billion in 2025 and is predicted to increase from USD 616.02 billion in 2026 to approximately USD 1,983.73 billion by 2035, expanding at a CAGR of 13.95% from 2026 to 2035.

According to Precedence Research, as the industry shifts toward biologics, biosimilars, and advanced therapies, complex manufacturing increasingly demands advanced lab technologies. Nova Biomedical focuses on improved integrated cell-line development enabled by NanoCellect's cell-sorting technology. Developing biologics requires stable, high-yielding cell lines, affecting manufacturing quality, efficiency, and scalability. Contract manufacturing organizations (CDMOs) benefit from flexible, scalable technologies that support multiple clients.

Integrated workflows reduce process variability, improve data quality, and aid regulatory compliance, helping manufacturers meet quality standards and avoid delays. Nova Biomedical's expanded portfolio accelerates biologic drug discovery, manufacturing, and delivery of innovative medicines. Integrated solutions improve efficiency and shorten project timelines. Additionally, a focus on digital transformation and automation in innovation lab practices aligns with these technologies. 

Impact on the Life Sciences Industry

The global life science market size is valued at USD 100.88 billion in 2025. It is predicted to increase from USD 112.93 billion in 2026 to approximately USD 305.98 billion by 2035, expanding at a CAGR of 11.73% from 2026 to 2035.

According to Precedence Research, life sciences research solutions favor all-in-one platforms over isolated tools to improve workflows, increase data management, and reduce training requirements. The integration of NanoCellect products into Nova Biomedical highlights a trend in Nova's expanding lineup by supporting automation that enhances discovery, accuracy, and compliance. As labs move towards modernization, demand for scalable, interoperable solutions increases.

Industry competition is growing as companies focus on acquisitions and partnerships and as customers value diverse solutions, software compatibility, and ongoing support to create connected ecosystems. This trend fosters advancements in AI, informatics, robotics, and automation. Nova Biomedical focuses on fostering innovation across life sciences support the importance of integrated lab technologies in driving discovery and therapies.

Expert Opinion

According to expert opinion, Nova Biomedical's integration of NanoCellect products reflects a broader industry transforming toward fully integrated lab ecosystems, which are crucial for biologic drug development. By combining cell sorting with analytical tools, it updates workflows, reduces manual work, improves data reliability, and supports regulatory compliance.

Strategically, it strengthens Nova's market position and highlights the importance of unified automation and analytics for innovation, enabling faster discovery, manufacturing, and advancement of precision medicine. This move reflects a trend toward wide-ranging platforms that enhance efficiency, data integration, and scalability, especially as biologics and gene therapies expand.